Skip to main content

Credelio for cats

Credelioâ„¢ (lotilaner) for cats: A comprehensive manuscript collection covering safety, onset of action, spectrum of activity and acceptability by pet cats of the first oral isoxazoline ectoparasiticide approved for use in cats and kittens.

​​​​​​​New Content ItemThis manuscript collection has been published to provide parasitologists and veterinarians a comprehensive view of the scientific data around the administration of Credelio (lotilaner) chewable tablets specifically designed for cats for the treatment of ectoparasites that infest pet cats and their environments around the world.

Ticks and fleas are common parasites of cats that are not only a nuisance, but cause harm and spread diseases like bartonellosis and cytauxzoonosis. The presence of ticks or fleas can lead to anemia. Immune response to flea bites may lead to Flea Allergy Dermatitis (FAD). Fleas can also transmit the tapeworm Dipylidium caninum to pet cats.

The articles in this collection describe the results of studies funded by Elanco Animal Health through the development of Credelio (lotilaner) for cats, providing information on its administration for the treatment of various ectoparasites. A detailed conflict of interest statement is included within each article.

The manuscripts in this collection have undergone the journal’s standard peer-review process overseen by the Editors, and each manuscript can also be found individually in the journal. The Editors of Parasites & Vectors declare no competing interests.

EDITORIAL
Lotilaner - a novel formulation for cats provides systemic tick and flea control
Ian Wright

Parasites & Vectors 2018 11:407
Published on: 13 July 2018

>Full Text          >PDF


RESEARCH
Laboratory evaluation of the efficacy and speed of kill of lotilaner (Credelioâ„¢) against Ctenocephalides felis on cats
Daniela Cavalleri, Martin Murphy, Wolfgang Seewald and Steve Nanchen

Parasites & Vectors 2018 11:408
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
Safety of lotilaner flavoured chewable tablets (CredelioTM) after oral administration in cats
Emmanuelle A. Kuntz and Srinivas Kammanadiminti

Parasites & Vectors 2018 11:409
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelioâ„¢) in controlling fleas in client-owned cats in Europe
Daniela Cavalleri, Martin Murphy, Wolfgang Seewald and Steve Nanchen

Parasites & Vectors 2018 11:410
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
A randomized, controlled field study to assess the efficacy and safety of lotilaner (Credelioâ„¢) in controlling ticks in client-owned cats in Europe
Daniela Cavalleri, Martin Murphy, Wolfgang Seewald and Steve Nanchen

Parasites & Vectors 2018 11:411
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
Céline E. Toutain, Wolfgang Seewald and Martin Jung

Parasites & Vectors 2018 11:412
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
Laboratory evaluation of the efficacy and speed of kill of lotilaner (CredelioTM) against Ixodes ricinus ticks on cats
Daniela Cavalleri, Martin Murphy, Wolfgang Seewald, Jason Drake and Steve Nanchen

Parasites & Vectors 2018 11:413
Published on: 13 July 2018

>Full text          >PDF


RESEARCH
A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelioâ„¢ CAT) in eliminating fleas in client-owned cats in the USA
Kimberly Chappell, Tandy Paarlberg, Wolfgang Seewald, Daniela Karadzovska and Steve Nanchen 

Parasites & Vectors 2021 14:127
Published on: 1 March 2021

>Full text          >PDF


RESEARCH
Efficacy of lotilaner (Credelioâ„¢) against experimentally induced infestations of the adult cat flea, Ctenocephalides felis, and flea eggs following oral administration to cats
Tandy Paarlberg, Daniela Karadzovska & Rainer Helbig 

Parasites & Vectors 2021 14:139
Published on: 5 March 2021

>Full text          >PDF